Last reviewed · How we verify
MB-102 DMID
MB-102 DMID is a monoclonal antibody targeting CD47.
MB-102 DMID is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | MB-102 DMID |
|---|---|
| Also known as | Relmapirazin |
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Drug class | monoclonal antibody |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CD47 is a protein that inhibits phagocytosis, and by targeting it, MB-102 DMID aims to stimulate the immune system to attack cancer cells.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |